Utility of support vector machine and decision tree to identify the prognosis of metformin poisoning in the United States: analysis of National Poisoning Data System

Omid Mehrpour1,2*, Farhad Saeedi3,4, Christopher Hoyte4,5, Foster Goss6,7 and Farshad M. Shirazi8

Abstract

Background: With diabetes incidence growing globally and metformin still being the first-line for its treatment, metformin’s toxicity and overdose have been increasing. Hence, its mortality rate is increasing. For the first time, we aimed to study the efficacy of machine learning algorithms in predicting the outcome of metformin poisoning using two well-known classification methods, including support vector machine (SVM) and decision tree (DT).

Methods: This study is a retrospective cohort study of National Poison Data System (NPDS) data, the largest data repository of poisoning cases in the United States. The SVM and DT algorithms were developed using training and test datasets. We also used precision-recall and ROC curves and Area Under the Curve value (AUC) for model evaluation.

Results: Our model showed that acidosis, hypoglycemia, electrolyte abnormality, hypotension, elevated anion gap, elevated creatinine, tachycardia, and renal failure are the most important determinants in terms of outcome prediction of metformin poisoning. The average negative predictive value for the decision tree and SVM models was 92.30 and 93.30. The AUC of the ROC curve of the decision tree for major, minor, and moderate outcomes was 0.92, 0.92, and 0.89, respectively. While this figure of SVM model for major, minor, and moderate outcomes was 0.98, 0.90, and 0.82, respectively.

Conclusions: In order to predict the prognosis of metformin poisoning, machine learning algorithms might help clinicians in the management and follow-up of metformin poisoning cases.

Keywords: Metformin, National Poison Data System, Support vector machine, Decision tree

Background

Diabetes has become a public health concern that gives rise to serious macrovascular and microvascular complications [1]. In 2015, there were approximately 415 million diabetes patients worldwide; this figure is expected to grow to over 600 million by 2040 [2]. Metformin is still the first-line therapy for diabetes among all medicines currently available [3]. However, even though metformin is a safe drug, poisoning can have a fatality rate of 30 to 50%, climbing to as much as 80% if done intentionally [4]. Due to the lack of an antidote and a conservative approach to managing metformin poisoning, early prognosis prediction based on initial presentation might be critical in diminishing the death rate. Some studies evaluated prognostic factors in metformin poisoning. These studies tried to emphasize the role of blood gas analysis in predicting the outcome [5, 6]. However, they reached different results. For
example, Kajbaf et al. showed that the lactate concentration and mean arterial pH was not significantly different between non-survivors and survivors diagnosed with metformin poisoning [5]. On the other hand, Shojaei Arani et al. found that HCO3− levels of less than 17.25 (mEq/L) and pH levels of less than 6.94 were associated with patient mortality among those with metformin poisoning [6]. This inconsistency might imply that using more sophisticated analysis such as AI might help physicians predict the outcome of metformin poisoning prognosis.

Medicine has paid much attention lately to new classification methods [7]. The fascinating part about machine learning techniques is that they can be taught how to assess medical risk predictions and simulate complicated clinical scenarios [8]. Thus, machine learning could boost precision medication delivery more than regression analysis [9]. Surprisingly, massive amounts of data heterogeneity can be combined using machine learning to uncover causal relationships between diseases and classify risk variables [10]. The decision tree (DT) examines the input data and shows the outcomes of the predicted relationships that have been identified as a consequence of the implementation of appropriate rules [11]. When dealing with huge amounts of variables and a limited sample size in medical research, the support vector machine (SVM) is another promising classification model [12]. SVM is a breakthrough tool that outputs findings while establishing a hyperplane, culminating in classification. Essentially, the underlying concept of SVM is to establish decision boundaries wherein characteristics are assessed concerning a hyperplane to demonstrate their significance. The attributes for which the hyperplane is drawn are called support vectors. Moreover, the distance between the hyperplane and the attributes is called margins. The optimal hyperplane is the one with the largest margin of support vectors.

The application of DT and SVM have been widely investigated among patients with drug overdose in recent times [13–15]. However, despite the serious outcomes, there has been no explicit application of machine learning techniques to study metformin overdose and provide a realistic strategy for determining the prognosis based on clinical and laboratory findings. Besides, although many of the important features of metformin poisoning are well known, machine learning algorithms to determine metformin poisoning are not studied yet. Artificial intelligence (AI) has been shown to help health care providers to diagnose diseases. Moreover, AI can aid physicians with their clinical decision-making and to predict the outcome [13, 16]. In addition, its performance in the field of medical toxicology received much attention recently [17–19]. However, it is important to understand how AI fits into large heterogeneous datasets and functions.

This study is the first study that used machine learning algorithms to predict metformin poisoning. We aimed to apply and test the decision tree and support vector machine models on a broad scale of patients with metformin overdose, taken from the National Poison Data System (NPDS), to evaluate the different categories of outcomes.

Methods

Study population and eligibility criteria

The data of this study was obtained from NPDS, which is the only real-time data repository of poisoning in the United States. American Association of Poison Control Centers (AAPCC) which maintains the NPDS, represents the 55 Poison Control Centers (PCCs). NPDS includes exposures to more than 400,000 substances that have been continuously reported by PCCs [20]. In addition, more than 2 million human exposure was reported to NPDS in 2019 [20]. Even though NPDS data does not contain all of the substance exposure in the country, every exposure reported to NPDS does not necessarily signify poisoning or toxicity. All metformin exposure cases reported to the NPDS between January 1, 2012, and December 31, 2017, were included in this study. However, we excluded those cases with missing data and duplicate ones. This study was not required Institutional review board approval based on the Colorado Multiple Institutional Review Board on Human Subjects Protection standards. All methods were carried out following relevant guidelines and regulations.

Definition of terms

To develop our classification model, we defined some important features based on the NPDS guidelines as follows:

- Hypertension: Diastolic blood pressure greater than 90 mmHg or systolic blood pressure greater than 140 mmHg
- Hypotension: Systolic blood pressure which is more than 15 mmHg less than usual systolic blood pressure that the patient has or less than 90 mmHg
- Elevated anion gap: Result of the following equation more than 12 mEq/L: \[Na^+ - (Cl^- + HCO3^-)\]
- Elevated creatinine: Creatinine level of more than 1.5 mg/dL or 133 μmol/L
- Tachycardia: Heart rate more than 100 beats per minute
- Renal failure: Acute and chronic renal failure that leads to clinically substantial loss of renal function and azotemia
Fig. 1 Decision tree model
Electrolyte abnormality: Imbalance level of sodium, potassium, bicarbonate, chloride, calcium, magnesium, and phosphate  

Hypoglycemia: Glucose levels of less than 70 mg/dL or 3.9 mmol/L  

Acidosis: Bicarbonate level less than 20 mEq/L, pH less than 7.35, or elevated levels of lactic acid  

Minor outcomes: The minimal bothersome symptoms, including skin or mucous membrane manifestations.  

Moderate outcomes: The symptoms that are not life-threatening but are more prolonged than minor symptoms.  

Major outcomes: The life-threatening symptoms leading to significant complications.

Development of classification model  
First, the dataset was randomly divided into training (70%) and testing (30%) datasets. The prediction model was developed by utilizing a train set and then incorporating the various variables, including demographic data (age, sex), the purpose of exposure (suicidal, unintentional, etc.), chronicity, clinical features, etc. Next, the test set was utilized to evaluate the model performance to see how well it fits the training set. Every decision tree comprises some nodes, including root and leaf nodes and branches. The root node denotes the most important feature, whereas the leaf node depicts a decision by applying some IF-THEN rules. For example, the right and left directions indicate false and true when moving down the decision tree's path. The evaluation of the decision tree model was performed through F-1 score, specificity, recall, precision, accuracy, and confusion matrix. ROC curves and precision-recall curves are provided for each model. Based on different probability thresholds, ROC curves illustrate the trade-off between true positive and false positive rates for a prediction model.

Using different probability thresholds, precision-recall curves summarize the trade-off between the true positive rate and positive predictive value of a predictive model. All the analyses were done in Python using the Sklearn library.

| Table 1 The rules driven from the decision tree model |
|------------------------------------------------------|
| If acidosis and renal failure occur, patients will develop a major outcome (100%) | 1 |
| If acidosis and hypotension occur while renal failure does not occur, patients are more likely to develop major outcomes (64.6%) | 2 |
| If acidosis and hypoglycemia are present, while renal failure and hypotension do not occur, patients are more likely to develop major outcomes (50%) | 3 |
| If acidosis occurs while renal failure, hypotension and hypoglycemia do not occur, patients are more likely to develop moderate outcomes (86%) | 4 |
| If a patient experiences hypoglycemia without acidosis, moderate outcomes are more likely (92.9%) | 5 |
| If a patient with an age of more than 59.5 experiences electrolyte abnormalities without acidosis, hypoglycemia, the development of major outcomes is more likely (66.7%) | 6 |
| If a patient with an age of less than 59.5 experiences electrolyte abnormalities without acidosis, hypoglycemia, the development of a moderate outcome is very likely (96.9%) | 7 |
| If tachycardia and hypertension are present, while acidosis, hypoglycemia and electrolyte abnormalities are not present, patients develop moderate outcomes (100%) | 8 |
| If tachycardia is present without acidosis, hypoglycemia, electrolyte abnormalities and hypertension, patients are likely to develop a minor outcome (50%) | 9 |
| If increased creatinine is present, while acidosis, hypoglycemia, electrolyte abnormalities and tachycardia are not present, patients are more likely to develop moderate outcomes (90%) | 10 |
| If an elevated anion gap is present, while acidosis, hypoglycemia, electrolyte abnormalities, tachycardia and elevated creatinine are not present, patients develop moderate outcomes (100%) | 11 |
| If a patient has an unintentional exposure without hypoglycemia, electrolyte abnormalities, tachycardia, elevated creatinine and elevated anion gap, the patient is more likely to develop minor outcomes (94.6%) | 12 |
| If acidosis does not occur, hypoglycemia does not occur, electrolyte abnormality does not exist, tachycardia does not exist, elevated creatinine does not exist, elevated anion gap does not exist, the reason for exposure is not unintentional, other miscellaneous are present, THEN patients are more likely to develop minor outcomes (71%) | 13 |
| If hypotension occurs, while acidosis, hypoglycemia, electrolyte abnormalities, tachycardia, elevated creatinine, elevated anion gap do not occur, other reason for exposure is unintentional, other miscellaneous are not present, patients are more likely to develop major outcomes (86.6%) | 14 |

Results  
Prognosis prediction based on decision tree  
A total of 2878 cases with metformin exposure were included in this study. The decision tree model and 15 rules-driven from it are shown in Fig. 1 and Table 1, respectively. The most important feature of our model is shown in Fig. 2. Our decision model comprises 10 levels,
15 leaf nodes, and 29 nodes. Acidosis was the most determined prognostic factor, followed by hypoglycemia and electrolyte abnormality.

Evaluation of the training and test datasets showed that although the significant levels of recall (training set: 96.42%; test set: 96.54%), precision (training set: 88.16%; test set: 86.21%), and F1-score (training set: 92.10%; test set: 91.08%) attributed to minor outcomes, while the greatest specificity (training set: 99.01%; test set: 98.37%) and belonged to major outcomes (Table 2). This evaluation also demonstrated 87.07 and 85.27% accuracy for training and test datasets. The confusion matrix showed that our model successfully identifies 1266 cases of minor outcomes, 529 cases of moderate outcomes, and 84 cases of major outcomes in the training set and 419 cases of minor outcomes, 167 cases of moderate outcomes, and 28 cases of major outcomes in test datasets (Table 3). The decision tree model's negative predictive value (NPV) for average, Major, Moderate, and Minor outcomes is 92.30, 97.79, 85.52, and 93.58, respectively. The AUC of the precision-recall curve for major, minor, and moderate outcomes was 0.51, 0.89, and 0.80, respectively (Fig. 3). The AUC of the ROC model for major, minor, and moderate outcomes was 0.92, 0.92, and 0.89, respectively (Fig. 4).

Prognosis prediction based on support vector machine
Evaluation of the training dataset of the SVM model showed that, despite the greatest specificity of major outcomes in both datasets (training set: 99.95%; test set: 98.67%) as well as the precision in the training set (98.92%), minor outcomes had the greatest recall (training set: 98.17%; test set: 97.69%) and F-1 score (training set: 92.60%; test set: 92.27%) in both datasets. The precision of test sets showed 87.42 and 87.43% for minor and major outcomes, respectively (Table 2). The training and test sets' accuracy was 88.92 and 86.80%, respectively. The confusion matrix showed that the SVM model could successfully identify 1289 cases of minor outcomes, 538 cases of moderate outcomes, 92 cases of major outcomes in the training set and 424 cases of minor outcomes, 174 cases of moderate outcomes, and 27 cases of major outcomes in test datasets (Table 3). The SVM model's negative predictive value (NPV) for average, Major, Moderate, and Minor outcomes is 93.30, 97.22, 87.06, and 95.62, respectively. The AUC of the precision-recall curve for major, minor, and moderate outcomes was 0.62, 0.91, and 0.68, respectively (Fig. 5). The AUC of the ROC model for major, minor, and moderate outcomes was 0.98, 0.90, and 0.82, respectively (Fig. 6).
Discussion
This study is a retrospective cohort study of NPDS data to propose an effective prediction approach to metformin poisoning outcomes. To the best of our knowledge, this is the first study to implement classification approaches in the outcome prediction of metformin poisoning. The current study showed that both DT and SVM algorithms are powerful tools for predicting metformin poisoning outcomes. Moreover, the SVM method predicted the prognosis of metformin poisoning more precisely than the decision tree.

The decision tree and the support vector machine are two of the most well-known machine learning techniques in medicine for uncovering unexplored areas of treatment, prognosis prediction, and diagnosis [21]. One of the important implications of the decision tree is establishing the intervention for groups of people of varying risk categories because there is a prejudice in selecting high-risk groups to define medical guidelines [22]. On the other hand, support vector machines obtain great accuracy when expressing the relationship between multiple elements via a linear feature [23].

Table 2 Characteristics for the training and test sets of SVM and DT

| Labels | Dataset     | Model | Major effect | Minor effect | Moderate effect | Average | Weighted average |
|--------|-------------|-------|--------------|--------------|----------------|---------|------------------|
| Specificity | Training Set | DT    | 0.990123 | 0.798817 | 0.938451 | 0.909130 | 0.856677 |
|          |             | SVM   | 0.999506 | 0.784615 | 0.961272 | 0.915131 | 0.856145 |
|          | Test Set    | DT    | 0.983752 | 0.765734 | 0.941300 | 0.896929 | 0.838008 |
|          |             | SVM   | 0.986706 | 0.786713 | 0.947589 | 0.907003 | 0.852953 |
| Precision | Training Set | DT    | 0.807692 | 0.881616 | 0.855987 | 0.848432 | 0.868604 |
|          |             | SVM   | 0.989247 | 0.876275 | 0.905724 | 0.923749 | 0.892954 |
|          | Test Set    | DT    | 0.717949 | 0.862140 | 0.856410 | 0.812166 | 0.851595 |
|          |             | SVM   | 0.750000 | 0.874227 | 0.874372 | 0.832866 | 0.866857 |
| Recall   | Training Set | DT    | 0.631579 | 0.964204 | 0.742978 | 0.779587 | 0.870714 |
|          |             | SVM   | 0.691729 | 0.981721 | 0.755618 | 0.809690 | 0.889249 |
|          | Test Set    | DT    | 0.651163 | 0.965438 | 0.687243 | 0.767948 | 0.852778 |
|          |             | SVM   | 0.627907 | 0.976959 | 0.716049 | 0.773638 | 0.868056 |
| F1_score | Training Set | DT    | 0.708861 | 0.921062 | 0.795489 | 0.808471 | 0.866553 |
|          |             | SVM   | 0.814159 | 0.926006 | 0.823890 | 0.854685 | 0.885421 |
|          | Test Set    | DT    | 0.682927 | 0.910870 | 0.762557 | 0.785451 | 0.847201 |
|          |             | SVM   | 0.683544 | 0.922742 | 0.787330 | 0.797872 | 0.862755 |
| Accuracy | Training Set | DT    | NaN     | NaN     | NaN     | NaN     | 0.870714 |
|          |             | SVM   | NaN     | NaN     | NaN     | NaN     | 0.889249 |
|          | Test Set    | DT    | NaN     | NaN     | NaN     | NaN     | 0.852778 |
|          |             | SVM   | NaN     | NaN     | NaN     | NaN     | 0.868056 |

Table 3 Confusion matrix for DT and SVM models in the training and test sets

| True Prediction | Dataset     | Model | Major effect | Minor effect | Moderate effect | Moderate effect |
|-----------------|-------------|-------|--------------|--------------|----------------|----------------|
| Major effect    | Training Set | DT    | 84           | 6            | 43             | 43             |
|                 |             | SVM   | 92           | 8            | 33             | 33             |
|                 | Test Set    | DT    | 28           | 2            | 13             | 13             |
|                 |             | SVM   | 27           | 1            | 15             | 15             |
| Minor effect    | Training Set | DT    | 1            | 1266         | 46             | 46             |
|                 |             | SVM   | 1            | 1289         | 23             | 23             |
|                 | Test Set    | DT    | 0            | 419          | 15             | 15             |
|                 |             | SVM   | 0            | 424          | 10             | 10             |
| Moderate effect | Training Set | DT    | 19           | 164          | 529            | 529            |
|                 |             | SVM   | 0            | 174          | 538            | 538            |
|                 | Test Set    | DT    | 11           | 65           | 167            | 167            |
|                 |             | SVM   | 9            | 60           | 174            | 174            |
In line with other studies, we also showed that acidosis, hypoglycemia, electrolyte abnormality, hypotension, elevated anion gap, elevated creatinine, tachycardia, renal failure, age, and unintentional exposure to metformin are the determinants of metformin poisoning prognosis. As we expected, acidosis and hypoglycemia are the most important factors in determining the outcome. Metformin-associated lactic acidosis (MALA) is a fatal condition following metformin poisoning and is accompanied by other gastrointestinal symptoms [24]. MALA has been reported to occur at up to 138 per 100,000 patients per year [25]. It should be noted that early diagnosis of MALA is critical, and it should be suspected in patients with creatinine concentrations of 256 mol/l or higher and
lactate concentrations of 8.4 mmol/l or higher [26]. MALA pathogenesis is attributed to a mitochondria blockage of the complex 1 respiratory chain [27]. In addition, lactic acidosis can cause an increase in anion production, which can lead to an increase in the anion gap [28].

Moreover, lactic acidosis is related to gastrointestinal loss, leading to hypovolemia, renal failure, and increased creatinine secondary to lactic acidosis, which can be recognized following metformin overdose [29]. We believe that this hypovolemia might cause hypotension and compensatory tachycardia. Metformin exposure can also reduce glucose absorption, lower hepatic glucose synthesis, and induce hypoglycemia [30].

In our study, we found that the accuracy of the SVM model in predicting the prognosis of metformin poisoning was higher than the DT model. The rationale behind
SVM classification is finding the decision boundary to separate different classes and maximize the margin [31]. As a result, this methodology performs well when the sample size is less than the dimensions. However, if additional dimensions are required, it is critical to include other factors such as the kernel and C function to develop a suitable model [12]. Furthermore, even if the data preparation and interpretation are comprehensible in the decision tree model, it cannot deal with the missing non-leaf node [32].

The strength of our study is that we used broad-scale data and introduced a classification approach with high accuracy that can be used in clinical practice. However, some limitations should be mentioned. Data collection of NPDS is based on self-reported cases, meaning that every exposure reported to the NPDS
might not be a case of poisoning or overdose. Even though NPDS is the largest database of poisoning in the United States, it does not reflect all of the exposure in the country. While many of the important features in metformin poisoning are known, the most important strength of this study is applying machine learning methods to bring and use these features in clinical practice. This study is a benchmark for other studies in this regard.

**Conclusion**

It is important to note that outcome prediction plays a crucial role in managing metformin poisoning. Our ML models to predict metformin poisoning outcomes were very
accurate, encouraging clinicians to use these algorithms in clinical practice. In line with other studies, our study also showed that acidosis, hypoglycemia, electrolyte abnormality, hypotension, elevated anion gap, elevated creatinine, tachycardia, and renal failure are the most important features in determining the prognosis of metformin poisoning. Besides, we found that the support vector model performs more accurately than the decision tree to predict the prognosis. These ML classification models organize our knowledge about metformin poisoning and illustrate the relationship of the important features that can lead to practical algorithms to predict the prognosis of metformin poisoning. Therefore, using machine learning algorithms in determining metformin poisoning is recommended.

Acknowledgments
The authors want to thank NPDS for its assistance in providing the data for this study.

Authors’ contributions
OM conceptualized and designed the study. All of the authors contributed to the writing. Final version of the manuscript was approved by all of the authors.

Funding
None.

Availability of data and materials
The datasets analyzed during the current study are not publicly available due to patients' privacy but are available from the corresponding author.

Declarations

Ethics approval and consent to participate
This article does not meet the federal definition of human subject's research.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflicts of interest in this study.

Author details
1 Data Science Institute, Southern Methodist University, Dallas, TX, USA. 2 Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA. 3 Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences (BUMS), Birjand, Iran. 4 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran. 5 University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 6 University of Colorado Hospital, Aurora, CO, USA. 7 Department of Emergency Medicine, University of Colorado Hospital, Aurora, CO, USA. 8 Arizona Poison & Drug Information Center, the University of Arizona, College of Pharmacy and University of Arizona, College of Medicine, Tucson, AZ, USA.

Received: 5 February 2022   Accepted: 27 June 2022

References
1. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3–16.
2. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
3. Flory J, Lipska K, Metformin in 2019. JAMA. 2019;321(19):1926–7.
4. Leonaviciute D, Madsen B, Schmedes A, Buus NH, Rasmussen BS. Severe metformin poisoning successfully treated with simultaneous Venovenous hemofiltration and prolonged intermittent hemodialysis. Case Rep Crit Care. 2018;2018:3868051.
5. Kajbaf F, Lalau JD. The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. BMC Pharmacol Toxicol. 2013;14:22. https://doi.org/10.1186/2050-6511-14-22 PMID: 23587368; PMCID: PMC3637618.
6. Shojaee Arani L, Shadnia S, Faraji Dana H, Bahmani K, Zamani N, Hassanian-Moghaddam H, et al. Prognostic factors in metformin intoxication: a case control study. Int Pharm Acta. 2021;4(1):4e1–4 Available from: https://journals.sbu.ac.ir/acta/article/view/34565.
7. Lee S-I, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Dehler VG, et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun. 2018;9(1):42.
8. Shameer K, Johnson KW, Glicksberg BS, Dudley JT, Sengupta PP. Machine learning in cardiovascular medicine: are we there yet? Heart. 2018;104(14):1156–64.
9. Chen JH, Asch SM. Machine learning and prediction in medicine – beyond the peak of inflated expectations. N Engl J Med. 2017;376(2):2507–9.
10. Johnson KW, Shameer K, Glicksberg BS, Readhead B, Sengupta PP, Bjorkergen JLM, et al. Enabling precision cardiologo through multiscale biology and systems medicine. ACC Basic Transl Sci. 2017;2(3):311–27.
11. Podgorerec V, Kokol P, Stingl B, Rozman I. Decision trees: an overview and their use in medicine. J Med Syst. 2002;26(5):445–63.
12. Yu W, Liu T, Valdez R, Gwinn M, Khoury MJ. Application of support vector machine modeling for prediction of common diseases: the case of diabetes and pre-diabetes. BMC Med Inform Decis Mak. 2010;10(1):16.
13. Mehrpour O, Nakhaee S, Mehrpour O. Risk assessment of elevated blood lead concentrations in the adult population using a decision tree approach. Drug Chem Toxicol. 2020;43(2):1–8.
14. Mehrpour O, uczynski A, Nezami H, Vaughn MG, Nakhaee S, Mehrpour O. Identifying risk factors for drug use in an Iranian treatment sample: a prediction approach using decision trees. Subst Use Misuse. 2018;53(6):1030–40.
15. Liu D, Yu M, Duncan J, Fondario A, Khraizi H, Nestadt PS. Discovering the unclassified suicide cases among undetermined drug overdose deaths using machine learning techniques. Suicide Life Threat Behav. 2020;SO(2):333–44.
16. Ratta Y, et al. Emergency department triage prediction of clinical outcomes using machine learning models. Crit Care. 2019;23(1):64.
17. Mehrpour O, Saeedi F, Hadianfar A. Prognostic factors of acetaminophen exposure in the United States: an analysis of 39,000 patients. Hum Exp Toxicol. 2021;40(12_suppl):5814–825.
18. Mehrpour O, Saeedi F, Hoyte C. Decision tree outcome prediction of acute acetaminophen exposure in the United States: a study of 30,000 cases from the National Poison Data System. Basic Clin Pharmacol Toxicol. 2022;123(1):191–9.
19. Mehrpour O, Hoyte C, Goss F, Shirazi FM, Nakhaee S. Decision tree algorithm can determine the outcome of repeated supratherapeutic ingestions (RSTI) exposure to acetaminophen: review of 4500 national poison data system cases. Drug Chem Toxicol. 2022;1–7.
20. Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Brooks DE, Ditbert KW, et al. 2019 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th annual report. Clin Toxicol (Phila). 2020;58(12):1360–541.
21. Kajbaf F, Lalau JD. The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. BMC Pharmacol Toxicol. 2013;14:22. https://doi.org/10.1186/2050-6511-14-22 PMID: 23587368; PMCID: PMC3637618.
22. Ramezankhani A, Hadavandi E, Pournik O, Shahrabi J, Azizi F, Hadaegh F. Decision tree-based modelling for identification of potential interactions between type 2 diabetes risk factors: a decade follow-up in a Middle East prospective cohort study. BMJ Open. 2016;6(12):e013336.
24. Goonoo MS, Morris R, Raithatha A, Creagh F. Republished: metformin-associated lactic acidosis: reinforcing learning points. Drug Ther Bull. 2021;59(8):124–7.
25. Lalau JD, Kajbaf F, Protti A, Christensen MM, De Broe ME, Wiensperger N. Metformin-associated lactic acidosis (MALA): moving towards a new paradigm. Diabetes Obes Metab. 2017;19(11):1502–12.
26. van Berlo-van de Laar IRF, Gedlik A, Riet E v ‘t, de Meijer A, Taxis K, Jansman FGA. Identifying patients with metformin associated lactic acidosis in the emergency department. International journal of. Clin Pharm. 2020;42(5):1286–92.
27. Owen MR, Dorian E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–14.
28. Blough B, Moreland A, Mora A Jr. Metformin-induced lactic acidosis with emphasis on the anion gap. Proc (Baylor Univ Med Cent). 2015;28(1):31–3.
29. Arroyo D, Melero R, Panizo N, Goicoechea M, Rodríguez-Benítez P, Vinuesa SG, et al. Metformin-associated acute kidney injury and lactic acidosis. Int J Nephrol. 2011;2011:749653.
30. Al-Abri SA, Hayashi S, Thoren KL, Olson KR. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. Clin Toxicol (Phila). 2013;51(5):444–7.
31. Verplancke T, Van Looy S, Benoit D, Vansteelandt S, Depuydt P, De Turck F, et al. Support vector machine versus logistic regression modeling for prediction of hospital mortality in critically ill patients with haematological malignancies. BMC Med Inform Decis Mak. 2008;8:56.
32. Uddin S, Khan A, Hossain ME, Moni MA. Comparing different supervised machine learning algorithms for disease prediction. BMC Med Inform Decis Mak. 2019;19(1):281.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.